Blog

Clinical Pharmacology Insights

Educational articles on pharmacokinetics, DMPK, dosing science, and regulatory guidance. Written for pharmacometricians, clinical pharmacologists, and DMPK scientists.

PK Basics

Absolute vs. Relative Bioavailability: Understanding the First-Pass Effect

Understand drug bioavailability (F), AUC comparisons, extravascular administration hurdles, and the devastating First-Pass Effect.

Mar 29, 20266 min read

PK Basics

Linear vs. Non-Linear Pharmacokinetics: Michaelis-Menten Explained

Explore the critical threshold where linear PK mathematics fail. Understand Michaelis-Menten kinetics, zero-order elimination, and drugs with unpredictable half-lives.

Mar 27, 20268 min read

Dosing

The Emax Model in Pharmacodynamics: Understanding Dose-Response

Delve into Pharmacodynamics with the Emax Model. Learn how EC50, Hill coefficients, and saturable binding define drug efficacy boundaries.

Mar 25, 20267 min read

DMPK

Allometric Scaling in Pharmacokinetics: From Animal to Human

Understand the mathematical framework of allometric scaling in DMPK. Learn how volume and clearance translate from mice, rats, and dogs to human projections.

Mar 22, 20268 min read

PK Basics

Mastering Non-Compartmental Analysis (NCA): Key Parameters Explained

Learn the fundamentals of NCA, the gold standard PK methodology for deriving AUC, Cmax, clearance, and volume of distribution.

Mar 20, 20269 min read

PK Basics

Understanding Drug Half-Life: A Complete Guide

Master drug half-life calculations, time to steady state, dosing intervals, and washout periods in pharmacokinetics. Includes formulas and clinical examples.

Mar 15, 20267 min read

DMPK

IVIVE: Predicting Human Clearance from In Vitro Data

A comprehensive deep dive into In Vitro-In Vivo Extrapolation (IVIVE), utilizing the well-stirred model, microsomal binding, and physiological scaling.

Mar 10, 20268 min read

Regulatory

FDA DDI Risk Assessment: The R1/R2/R3 Framework Explained

Navigate the 2020 FDA DDI Guidance. Understand R1, R2, and AUCR static models to evaluate drug-drug interaction risk accurately.

Mar 5, 20268 min read